Sipeki N, Kovats PJ, Deutschmann C, Schierack P, Roggenbuck D, Papp M. Location-based prediction model for Crohn’s disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies. World J Gastroenterol 2023; 29(42): 5728-5750 [PMID: 38075846 DOI: 10.3748/wjg.v29.i42.5728]
Corresponding Author of This Article
Nora Sipeki, MD, PhD, Assistant Lecturer, Attending Doctor, Doctor, Postdoc, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei blv 98, Debrecen H-4032, Hungary. sipeki.nora@med.unideb.hu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Stability of anti-chitinase 3-like 1 autoantibodies status over time in patients with Crohn’s disease during the disease course
Serologic antibodies
(Sub)type
n
Stable negative, n (%)
Stable positive, n (%)
Negative to positive, n (%)
Positive to negative, n (%)
aCHI3L1
IgG
165
152 (92.1)
2 (1.2)
2 (1.2)
9 (5.5)
IgA
165
92 (55.8)
39 (23.6)
17 (10.3)
17 (10.3)
sIgA
165
83 (50.3)
51 (30.9)
14 (8.5)
17 (1.1)
Table 4 Association of anti-chitinase 3-like 1 autoantibodies antibody formation with clinical, serological, and genetic characteristics of Crohn’s disease at diagnosis and last follow-up
Anti-CHI3L1
IgA
sIgA
OR (95%CI)
P value
OR (95%CI)
P value
At diagnosis
Complicated disease behaviour
1.86 (0.97-3.55)
0.081
2.37 (1.26-4.48)
0.009
Colon involvement
6.61 (2.29-19.07)
< 0.0001
2.09 (1.07-4.10)
0.038
ASCA IgA
4.11 (2.24-7.55)
< 0.0001
4.16 (2.40-7.19)
< 0.0001
OMP IgA
3.16 (1.79-5.57)
< 0.0001
2.64 (1.57-4.44)
< 0.0001
Anti-PS/PT IgA
3.46 (1.49-8.04)
0.005
2.56 (2.15-14.58)
< 0.0001
Anti-GP2 IgA
4.76 (0.87-26.18)
0.108
9.47 (1.12-79.52)
0.018
At last visit
Frequent relapse
2.56 (1.34-4.91)
0.005
1.89 (1.00-3.56)
0.047
Table 5 Univariate and multivariate Cox regression analyses evaluating the association between clinical and serologic variables and the study end-point events (complicated disease course) in Crohn’s disease patients. Subgroup analysis of B1 patients with colonic involvement is shown in the second half of the table
Development of internal penetrating and/or stenotic complication in B1 patients at diagnosis
Development of internal penetrating and/or stenotic complication in B1 patients at diagnosis with colonic involvement
Table 6 Univariate and multivariate Cox regression analyses evaluating the association between clinical and serologic variables and the study end-point events (development of perianal complications) in Crohn’s disease patients. Subgroup analysis of B1 patients with colonic involvement is shown in the second half of the table
Development of perianal penetrating complication in P0 patients at diagnosis
Development of perianal penetrating complication in P0 patients at diagnosis with colonic involvement
Table 7 Univariate and multivariate Cox regression analyses evaluating the association between clinical and serologic variables and the study end-point events (need for resective surgery) in Crohn’s disease patients. Subgroup analysis of B1 patients with colonic involvement is shown in the second half of the table
Need for resective surgery in B1 patients at diagnosis
Need for resective surgery in B1 patients at diagnosis with colonic involvement
Table 8 Univariate and multivariate Cox regression analyses evaluating the association between clinical and serologic variables and the study end-point events (reoperation after resection) in Crohn’s disease patients. Subgroup analysis of B1 patients with colonic involvement is shown in the second half of the table
Need for resective surgery in B1 patients with previous CD-related abdominal surgery
Need for resective surgery in B1 patients with previous CD-related abdominal surgery and colonic involvement
Citation: Sipeki N, Kovats PJ, Deutschmann C, Schierack P, Roggenbuck D, Papp M. Location-based prediction model for Crohn’s disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies. World J Gastroenterol 2023; 29(42): 5728-5750